Subtopic Deep Dive
Genetic Testing for BRCA Variants
Research Guide
What is Genetic Testing for BRCA Variants?
Genetic testing for BRCA variants involves laboratory analysis to detect pathogenic mutations in BRCA1 and BRCA2 genes for assessing hereditary cancer risk.
Multigene panel testing identifies BRCA variants alongside other predisposition genes, with germline mutations found in 8.5% of pediatric cancer cases (Zhang et al., 2015, 1300 citations). BRCA mutation frequency in ovarian cancer ranges from 3% to 27%, influencing treatment response (Alsop et al., 2012, 1144 citations). Testing enables risk assessment for breast, ovarian, and contralateral breast cancer in carriers (Kuchenbaecker et al., 2017, 2687 citations).
Why It Matters
Genetic testing identifies BRCA mutation carriers eligible for PARP inhibitors like olaparib, showing antitumor activity in BRCA-associated cancers (Fong et al., 2009, 3582 citations). Risk-reducing salpingo-oophorectomy reduces breast and gynecologic cancer risks in BRCA carriers (Kauff et al., 2002, 1244 citations). Adjuvant olaparib improves outcomes in BRCA-mutated breast cancer post-chemotherapy (Tutt et al., 2021, 1531 citations). Population screening feasibility supports preventive interventions amid rising ovarian cancer incidence (Torre et al., 2018, 3619 citations).
Key Research Challenges
Variant of Uncertain Significance
Variants of uncertain significance (VUS) in BRCA testing complicate clinical interpretation and risk counseling. Resolution requires functional assays and segregation analysis, as seen in pediatric cancer germline studies (Zhang et al., 2015). Over 27% mutation frequency variability in ovarian cancer highlights VUS challenges (Alsop et al., 2012).
Population Screening Feasibility
Broad screening feasibility faces cost, access, and ethical barriers despite high cancer risks in carriers. Prospective data show family history inadequately predicts mutations (Kuchenbaecker et al., 2017). Implementation needs scalable protocols beyond high-risk cohorts (Torre et al., 2018).
Psychosocial Implementation Barriers
Ethical and psychosocial impacts of testing include anxiety and informed consent issues in diverse populations. Germline testing in pancreatic cancer reveals maintenance therapy benefits but uptake challenges (Golan et al., 2019). Integration into clinical workflows remains inconsistent (Tutt et al., 2021).
Essential Papers
Ovarian cancer statistics, 2018
Lindsey A. Torre, Britton Trabert, Carol DeSantis et al. · 2018 · CA A Cancer Journal for Clinicians · 3.6K citations
Abstract In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an ove...
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · 2009 · New England Journal of Medicine · 3.6K citations
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NC...
Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes et al. · 2017 · JAMA · 2.7K citations
These findings provide estimates of cancer risk based on BRCA1 and BRCA2 mutation carrier status using prospective data collection and demonstrate the potential importance of family history and mut...
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
Talia Golan, Pascal Hammel, Michele Reni et al. · 2019 · New England Journal of Medicine · 2.1K citations
Among patients with a germline <i>BRCA</i> mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and ot...
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer
Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · 2021 · New England Journal of Medicine · 1.5K citations
Among patients with high-risk, HER2-negative early breast cancer and germline <i>BRCA1</i> or <i>BRCA2</i> pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local trea...
Awareness and current knowledge of breast cancer
Muhammad Akram, Mehwish Iqbal, Muhammad Daniyal et al. · 2017 · Biological Research · 1.3K citations
Breast cancer remains a worldwide public health dilemma and is currently the most common tumour in the globe. Awareness of breast cancer, public attentiveness, and advancement in breast imaging has...
Germline Mutations in Predisposition Genes in Pediatric Cancer
Jinghui Zhang, Michael F. Walsh, Gang Wu et al. · 2015 · New England Journal of Medicine · 1.3K citations
Germline mutations in cancer-predisposing genes were identified in 8.5% of the children and adolescents with cancer. Family history did not predict the presence of an underlying predisposition synd...
Reading Guide
Foundational Papers
Start with Fong et al. (2009, 3582 citations) for PARP inhibition linking testing to therapy; Kauff et al. (2002, 1244 citations) for risk-reducing surgery outcomes in carriers; Alsop et al. (2012, 1144 citations) for mutation frequency baselines.
Recent Advances
Study Tutt et al. (2021, 1531 citations) for adjuvant olaparib in breast cancer; Golan et al. (2019, 2107 citations) for pancreatic applications; Kuchenbaecker et al. (2017, 2687 citations) for refined risk estimates.
Core Methods
Germline sequencing via multigene panels (Zhang et al., 2015); PARP inhibitor response testing (Fong et al., 2009); prospective cohort risk modeling (Kuchenbaecker et al., 2017).
How PapersFlow Helps You Research Genetic Testing for BRCA Variants
Discover & Search
PapersFlow's Research Agent uses searchPapers and exaSearch to find BRCA testing literature, such as 'BRCA Mutation Frequency... Ovarian Cancer' by Alsop et al. (2012), then citationGraph reveals 1144 citing papers on variant resolution. findSimilarPapers expands to multigene panels from Zhang et al. (2015).
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation frequencies from Alsop et al. (2012), verifies claims with CoVe against Kuchenbaecker et al. (2017), and runs PythonAnalysis on risk data for statistical significance (e.g., NumPy t-tests on carrier risks). GRADE grading scores evidence from Fong et al. (2009) as high for PARP response.
Synthesize & Write
Synthesis Agent detects gaps in VUS resolution protocols across Fong et al. (2009) and Tutt et al. (2021), flags contradictions in screening feasibility. Writing Agent uses latexEditText, latexSyncCitations for BRCA review manuscripts, latexCompile for publication-ready PDFs, and exportMermaid for mutation pathway diagrams.
Use Cases
"What is the germline BRCA mutation rate in ovarian cancer patients?"
Research Agent → searchPapers('BRCA ovarian cancer germline') → Analysis Agent → readPaperContent(Alsop 2012) + runPythonAnalysis (citation count pandas plot) → outputs 3-27% frequency table with 1143 similar papers.
"Generate LaTeX review on adjuvant olaparib for BRCA breast cancer."
Synthesis Agent → gap detection(Tutt 2021 + Kuchenbaecker 2017) → Writing Agent → latexEditText(draft) → latexSyncCitations(Fong 2009) → latexCompile → outputs compiled PDF with risk tables and citations.
"Find analysis code for BRCA variant risk models."
Research Agent → paperExtractUrls(Zhang 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs Python scripts for mutation frequency stats from pediatric cancer data.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ BRCA testing papers: searchPapers → citationGraph(Fong 2009) → DeepScan 7-steps with GRADE checkpoints → structured report on VUS resolution. Theorizer generates hypotheses on population screening from Alsop et al. (2012) risks chained to Kauff et al. (2002) interventions. DeepScan verifies olaparib trial claims (Tutt 2021) via CoVe across 10 papers.
Frequently Asked Questions
What is genetic testing for BRCA variants?
Laboratory sequencing detects pathogenic germline mutations in BRCA1/BRCA2 genes to assess hereditary breast/ovarian cancer risk (Kuchenbaecker et al., 2017). Multigene panels include these alongside other genes (Zhang et al., 2015).
What methods are used in BRCA testing?
Next-generation sequencing panels identify mutations; functional assays resolve VUS (Alsop et al., 2012). Germline testing precedes PARP inhibitor therapy (Fong et al., 2009).
What are key papers on BRCA testing?
Alsop et al. (2012, 1144 citations) reports 3-27% ovarian cancer mutation frequency. Kuchenbaecker et al. (2017, 2687 citations) estimates carrier risks. Zhang et al. (2015, 1300 citations) finds 8.5% in pediatric cancers.
What open problems exist in BRCA testing?
VUS interpretation and population screening scalability persist (Alsop et al., 2012). Psychosocial impacts and access equity need resolution (Torre et al., 2018). Integration with therapies like olaparib requires better protocols (Tutt et al., 2021).
Research BRCA gene mutations in cancer with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Genetic Testing for BRCA Variants with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers
Part of the BRCA gene mutations in cancer Research Guide